Generic Injectable Market

2019 Analysis and Review of Generic Injectable Market by Product - Monoclonal Antibodies, Immunoglobulins, Cytokines, Insulin, Peptide Hormones, Blood Factors, Peptide Antibiotics, Vaccines, Small Molecule Antibiotics, Chemotherapy Agents, and Others for 2019 - 2029

  • 2020-02-20
  • REP-GB-6051
  • 66 Tables
  • 90 Figures
  • 239 pages
  • Format: PDF/PPT/Excel
  • SELECT LICENSE :

  • US$5,000
  • US$7,500
  • US$10,000

Generic Injectable Market Size to Expand 3X by 2029

Commercially, the global injectable market has been in its nascent phase in the recent past. However, inequalities in the supply-demand of various drugs have influenced market players to focus on expanding their manufacturing and distribution capabilities. Governments are also playing a pivotal role by boosting capital allocation for the healthcare sector, especially in oncology research and biologics production. Moreover, patients are preferring self-drug administration such as pre-filled syringes to avoid caregiver fees. Together, these activities are offering fertile ground for generic injectable manufacturers. Exhibiting a double-digit CAGR, worldwide revenue of the generic injectable market will surge threefold by 2029.

Frequently Asked Questions about Generic Injectable Market

What are the factors contributing to the growth of the generic injectable market?

Growing focus on targeted therapies and biologics, particularly in the area of cancer, is increasing the need for generic injectable drugs. Biological injectable drugs hold a notable share of the generic injectable market. Adoption of generic injectables in small molecules is anticipated to gain significant traction.

What are the promising strategies for large manufacturers and small local players in the generic injectable market?

Overall, leaders in the generic injectable market are expected to have a wide portfolio and low-cost products, and local players will have truly distinguished offerings. To achieve higher cost savings, government healthcare facilities are now adopting higher utilization of generic injectables in their services.

How are CMOs affecting the growth of the generic injectable market?

Outsourcing manufacturing of generic injectable drugs to CMOs and CDMOs led to significant cost savings among key drug makers, who were facing capital investment issues with high levels of debt.

How is the cost associated with generic injectables hampering market growth in emerging economies?

Heightened competition from low-cost manufacturing countries such as China and India led to the suspension of many products in the segment for economies of scale. This is offering growth opportunity for low-cost manufacturers to gain significant share of the generic injectable market.

Which region is expected to offer lucrative growth opportunities for the generic injectable market?

North America and Europe, being highly mature markets with higher concentration of manufacturers and healthcare resources, are estimated to drive the growth of the global generic injectable market. Furthermore, East Asia and South Asia are expected to be lucrative regions, as a majority of manufacturers of low-cost generic injectables are focusing on establishing facilities in these regions.

How is the competition scenario in the generic injectable market?

Key manufacturers in the generic injectable market such as Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., and Sanofi S.A. are aiming at inorganic and organic business expansions strategies by entering into mergers, sales agreements, partnerships, and production partnerships with local manufactures from developing economies.

Manufacturers Prefer Monoclonal Antibodies to Develop Generic Injectables

Given their higher biosimilar capabilities and cost benefits over branded injectable drugs, demand for monoclonal antibodies (mAbs) stays atop in the generic injectable market. Procuring around a quarter of overall market value, manufacturers prefer mAb drugs for treating various chronic disorders, including cancer and other autoimmune diseases. Rising prominence of single-use technologies and closed delivery systems are transforming vaccine manufacturing, particularly in addressing the challenge of sterilization. Market players are thus driving innovations in the development and delivery of vaccines.

Developed Regions Maintain their Primacy

Capturing a significant chunk of total market revenue, collectively, North America and Europe are the hub of value-creation prospects for manufacturers. The presence of a well-established healthcare system and increasing rate of drug approvals are auguring well for the generic injectable market in these developed regions. Further, North America and Europe would share nearly identical divide in the market landscape by 2029 end. Driven by drastic upsurge in production capacity and technology intervention in the pharmaceutical industry, manufacturers are also targeting Asia for further investment opportunities.

Reimagining Supplier Ecosystems with CMOs

Contract manufacturing organizations (CMOs) play an instrumental role in spurring network disruptions in the healthcare vertical. Moreover, recent projections suggest that, CMOs are likely to flourish nearly twice that of the entire medtech industry in the near future. Market incumbents are outsourcing the manufacturing of generic injectable drugs to CMOs in order to ensure significant savings in capital expenses (CAPEX). Furthermore, with a proper approach, CMOs help them manage volatilities in demand and tackle supply risks. As such, players in the generic injectable market would be well placed to expand their customer base with quality-focused products and services.

Monoclonal antibodies remain highly preferred

Vaccines to gain rapid traction

High preference for small molecule drugs

Large molecule drugs to show noteworthy CAGR

High adoption in pain management

Application in infectious diseases on rise

Hospital pharmacies account for leading value share

Retail pharmacies to exhibit higher growth rate

How Growth will Unfold

Small molecules have been a mainstay in the manufacturing of generic injectable drugs, primarily attributable to the favorable regulatory framework. However, large molecule drugs, or biologic drugs, are emerging as a major shake-up in the biotechnology industry, owing to their greater specificity and safety profile in injectable drug delivery. By 2022, large molecule generic injectables will outperform the small molecule iterations. These paradigm shifts are compelling generic injectable manufacturers to re-think every facet of their approaches.

Preferential Analysis of Generic Injectable Market by Molecule Type

* This data is only a representation. Actual data may vary and will be available in report.

Click Here To Know How The Growth Will Unfold

Custom Market Research Services

FMI offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Overview

Generic Injectable Market Analysis 2019-2029

A recent market study published by Future Market Insights (FMI) offers global industry analysis of 2014-2018 and forecasts for 2019-2029. The study also offers a comprehensive assessment of the most important market dynamics. After conducting thorough research on the historical as well as current growth parameters of the generic injectable market, the growth prospects of the market are obtained with maximum precision.

Generic Injectable Market Taxonomy

The global generic injectable market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

Product

  • Monoclonal Antibodies
  • Immunoglobulins
  • Cytokines
  • Insulin
  • Peptide Hormones
  • Blood Factors
  • Peptide Antibiotics
  • Vaccines
  • Small Molecule Antibiotics
  • Chemotherapy Agents
  • Others

Molecule Type

  • Small Molecules
  • Large Molecules

Application

  • Oncology
  • Infectious Diseases
  • Diabetes
  • Blood Disorders
  • Hormonal Disorders
  • Musculoskeletal Disorders
  • CNS Diseases
  • Pain Management
  • Cardiovascular Diseases

Route of Administration

  • Intravenous (IV)
  • Intramuscular (IM)
  • Subcutaneous (SC)

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

Region

  • North America
  • Europe
  • Latin America
  • South Asia
  • East Asia
  • Oceania
  • Middle East And Africa

What's Included

The report commences with the executive summary of the generic injectable market, which includes a summary of the key findings and key statistics of the market. It also includes the market value (US$ billion) estimates of the leading segments of the generic injectable market.

Readers can find the detailed segmentation and the definition of the generic injectable market in this chapter, which will help them understand the basic information about the generic injectable market. This section also highlights the inclusions and exclusions, which helps the reader understand the scope of the generic injectable market report.

The generic injectable market report provides the key market trends that are expected to significantly impact the market growth during the forecast period. Detailed industry trends are provided in this section.

This section includes the factors that have emerged as key successful factors and the strategies adopted by key market participants. Additional viewpoint on global average pricing analysis benchmark, consumer sentiment analysis, and value chain analysis, which are likely to contribute to market growth.

This section explains the global market value analysis and forecast for the generic injectable market between the forecast periods of 2019-2029. This chapter includes a detailed analysis of the historical generic injectable market, along with an opportunity analysis of the future. Readers can also find the absolute $ opportunity for the current year (2019), and an incremental $ opportunity for the forecast period (2019–2029). Along with this, pricing analysis of the generic injectable market at the regional level has been provided in this section. This section also explains the global market volume analysis and forecast for the generic injectable market during the forecast period.

This chapter explains the key macroeconomic factors that are expected to influence the growth of the generic injectable market during the forecast period. Along with the macroeconomic factors, this section also highlights the impact factors, supply chain, forecast factors, Porter’s five forces analysis, and value chain analysis for the generic injectable market. Moreover, in-depth information about the market dynamics and their impact analysis on the market have been provided in the successive section. Moreover, readers will understand the key trends followed by the leading manufacturers in the generic injectable market.

Based on product, the generic injectable market is segmented into monoclonal antibodies, immunoglobulin, cytokines, insulin, peptide hormones, blood factors, peptide antibiotics, vaccines, small molecule antibiotics, chemotherapy agents, and others. Readers can find information about the key trends and developments in the generic injectable market and market attractiveness analysis based on product type.

Based on molecule type, the generic injectable market is segmented into small molecule, and large molecule. In this chapter, readers can find information about the key trends and developments in the generic injectable market and market attractiveness analysis based on application of generic injectable.

Based on application, the generic injectable market is segmented into oncology, infectious diseases, diabetes, blood disorders, hormonal disorders, musculoskeletal disorders, CNS diseases, pain management, and cardiovascular diseases. In this chapter, readers can find information about the key trends and developments in the generic injectable market and market attractiveness analysis based on application of generic injectable.

Based on route of administration, the generic injectable market is segmented into intravenous (IV), intramuscular (IM), and subcutaneous (SC). In this chapter, readers can find information about the key trends and developments in the generic injectable market and market attractiveness analysis based on application of generic injectable.

This chapter provides details about the generic injectable market on the basis of distribution channel, and has been classified into hospital pharmacies, retail pharmacies, drug stores, and online pharmacies. In this chapter, readers can understand the market attractiveness analysis based on distribution channel.

This chapter explains how the generic injectable market will grow across various geographic regions, such as North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East & Africa (MEA).

This chapter includes a detailed analysis of the growth of the North America, along with a country-wise assessment that includes the U.S. and Canada.

Readers can find detailed information about several factors such as the pricing analysis, which are impacting growth of the Latin America generic injectable market. This chapter also includes the growth prospects of the generic injectable market in the leading Latin America countries such as Brazil, Mexico, and the Rest of Latin America.

Important growth prospects of the generic injectable market based on its end users in several countries such as Germany, the UK, France, Spain, Italy, Russia, and the Rest of Europe, are included in this chapter.

India, Indonesia, Thailand, and Malaysia are among the leading countries in the South Asia region, which are the prime subjects of assessment to obtain the growth prospects of the South Asia generic injectable market in this chapter. Readers can find detailed information about the growth parameters of the South Asia Generic injectable market during the period 2019–2029.

This chapter highlights the growth of the generic injectable market in East Asia by focusing on China, Japan, and South Korea. This section also helps readers understand the key factors that are responsible for the growth of the generic injectable market in East Asia.

In this chapter, Australia and New Zealand are among the leading countries in the Oceania region, which are the prime subjects of assessment to obtain the growth prospects of the Oceania generic injectable market.

This chapter provides information about how the generic injectable market will grow in the major countries in the MEA region such as GCC Countries, South Africa, Turkey, and the rest of MEA, during the forecast period.

This chapter provides information about how the generic injectable market in emerging countries will grow during the forecast period.

In this chapter, readers can find detailed information about the tier analysis and market concentration of the key players in the generic injectable market, along with their market presence analysis by region and product portfolio.

In this chapter, readers can find a comprehensive list of all the leading stakeholders in the generic injectable market, along with detailed information about each company, which includes the company overview, revenue shares, strategic overview, and recent company developments. Some of the market players featured in the report are Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi S.A., Sun Pharmaceutical Industries Ltd., AstraZeneca Plc, Merck & Co., Inc., Mylan N.V, Cipla Inc., Dr. Reddy’s Laboratories Ltd., Samsung Biologics., and others.

This chapter includes a list of acronyms and assumptions that provide a base to the information and statistics included in the generic injectable market report.

This chapter helps readers understand the research methodology followed to obtain the various conclusions as well as important qualitative and quantitative information about the generic injectable market.

How the research was conducted?

Primary Research

  • C - Level Executives
  • Marketing Directors
  • Sales Heads
  • Portfolio Managers
  • Purchasing Managers
  • Medical Officers
  • Device Development Heads
  • Strategy Advisors
  • R&D Managers
  • Product Manufacturers
  • Distributors
  • Component Suppliers / OEMs
  • Purchasing Departments
  • Physicians / Nursing Managers
  • Industry Experts
  • Current Market Dynamics and Challenges
  • Market Characteristics
  • Market Performance and Growth Quadrants
  • Competition Structure and Market Structure
  • Strategic Growth Initiatives
  • Product Adoption, utilization rate, substitutes
  • Regulatory Landscape
  • Products in Pipeline and Clinical Development
  • Near-term and Long-term Market Growth Prospects
  • Market Segment Splits and Authenticity
  • Opinions on Market Projections and Validity of Assumptions

Secondary Research

  • Industry Magazines
  • Factiva
  • Organisation for Economic Co-operation and Development
  • Emergency Care Research Institute
  • Global Clinical research Organizations
  • Research organisations 
  • Company Press Releases
  • Annual Reports and Investor Presentations
  • Peer-reviewed Journals
  • Government Websites and Publications
  • Trade Websites
  • Clinical Trial Registries
  • Country-specific Regulatory Authorities
  • World Bank, WHO

Primary Interview Splits

Primary Interview Splits generic injectable market designation

Primary Interview Splits generic injectable market stakeholders

To Learn More About our Comprehensive Perspective on Generic Injectable Market,

Get in touch

Harish Tiwari

Global Head - Business Development

Akshay Godge

Client Partner - Global Business Development

COVID -19 : Impact Analysis

Request the coronavirus impact analysis across industries and markets

Request Covid -19 Impact

Our Clients


CASE STUDIES

See how our work makes an impact.

At FMI, we design strategies that are adaptive, impactful, and implementable.

Request Sample Ask An Analyst Request Methodology